| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 12 | 2026 | 154 | 2.310 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2025 | 443 | 2.290 |
Why?
|
| Leukemia, Myeloid, Acute | 19 | 2025 | 849 | 2.010 |
Why?
|
| Myelodysplastic Syndromes | 11 | 2026 | 385 | 1.980 |
Why?
|
| Primary Myelofibrosis | 6 | 2024 | 72 | 1.960 |
Why?
|
| Neoplastic Stem Cells | 4 | 2025 | 189 | 0.990 |
Why?
|
| Gene Expression Regulation, Leukemic | 7 | 2025 | 100 | 0.920 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2017 | 77 | 0.920 |
Why?
|
| MicroRNAs | 8 | 2017 | 604 | 0.890 |
Why?
|
| Hematologic Neoplasms | 3 | 2026 | 383 | 0.820 |
Why?
|
| Leukemia, B-Cell | 2 | 2022 | 22 | 0.810 |
Why?
|
| Erythrocytes | 2 | 2020 | 242 | 0.810 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 125 | 0.800 |
Why?
|
| Megakaryocytes | 7 | 2026 | 39 | 0.790 |
Why?
|
| Mutation | 23 | 2025 | 4396 | 0.780 |
Why?
|
| Neoplasm Proteins | 12 | 2021 | 551 | 0.720 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2021 | 137 | 0.710 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2022 | 33 | 0.700 |
Why?
|
| Nuclear Proteins | 7 | 2026 | 750 | 0.690 |
Why?
|
| Sarcoma | 1 | 2023 | 222 | 0.670 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2021 | 48 | 0.660 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2020 | 11 | 0.650 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2020 | 977 | 0.650 |
Why?
|
| Down Syndrome | 6 | 2023 | 54 | 0.640 |
Why?
|
| Hematopoietic Stem Cells | 9 | 2023 | 331 | 0.610 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 7 | 2016 | 78 | 0.610 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 12 | 0.600 |
Why?
|
| Humans | 92 | 2026 | 97898 | 0.600 |
Why?
|
| Repressor Proteins | 5 | 2025 | 448 | 0.600 |
Why?
|
| Anemia, Sickle Cell | 1 | 2020 | 158 | 0.540 |
Why?
|
| Leukemia, Myeloid | 4 | 2021 | 241 | 0.530 |
Why?
|
| RNA Interference | 2 | 2017 | 388 | 0.530 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 195 | 0.460 |
Why?
|
| Mice | 36 | 2026 | 12702 | 0.460 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2026 | 682 | 0.450 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2003 | 119 | 0.450 |
Why?
|
| Leukemia | 5 | 2022 | 308 | 0.440 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 4 | 2012 | 9 | 0.440 |
Why?
|
| Lymphoma, B-Cell | 3 | 2022 | 110 | 0.430 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 2014 | 9 | 0.420 |
Why?
|
| Homeodomain Proteins | 7 | 2024 | 566 | 0.420 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 32 | 0.410 |
Why?
|
| Hematology | 2 | 2020 | 37 | 0.410 |
Why?
|
| Hematopoiesis | 3 | 2018 | 187 | 0.400 |
Why?
|
| DNA-Binding Proteins | 8 | 2016 | 1254 | 0.400 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 117 | 0.400 |
Why?
|
| Gene Rearrangement | 5 | 2021 | 175 | 0.400 |
Why?
|
| Lymphoma, T-Cell | 4 | 2022 | 60 | 0.390 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 118 | 0.390 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2025 | 462 | 0.390 |
Why?
|
| Warts | 1 | 2013 | 12 | 0.380 |
Why?
|
| Lymph Nodes | 4 | 2022 | 560 | 0.380 |
Why?
|
| Bone Marrow | 6 | 2022 | 420 | 0.380 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2013 | 38 | 0.380 |
Why?
|
| Agammaglobulinemia | 1 | 2013 | 21 | 0.380 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2016 | 171 | 0.380 |
Why?
|
| Apoptosis | 14 | 2016 | 1752 | 0.370 |
Why?
|
| Immunophenotyping | 6 | 2021 | 227 | 0.370 |
Why?
|
| Neutropenia | 1 | 2013 | 211 | 0.360 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2022 | 111 | 0.350 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2022 | 28 | 0.350 |
Why?
|
| Multiple Myeloma | 4 | 2022 | 369 | 0.350 |
Why?
|
| Immunohistochemistry | 7 | 2022 | 1815 | 0.350 |
Why?
|
| Animals | 43 | 2026 | 28907 | 0.350 |
Why?
|
| Aminopyridines | 2 | 2023 | 54 | 0.350 |
Why?
|
| Triazines | 2 | 2023 | 55 | 0.350 |
Why?
|
| Carrier Proteins | 2 | 2025 | 667 | 0.340 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2010 | 186 | 0.340 |
Why?
|
| F-Box Proteins | 2 | 2026 | 15 | 0.340 |
Why?
|
| Bacterial Infections | 1 | 2013 | 184 | 0.340 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 68 | 0.330 |
Why?
|
| Neoplasms, Second Primary | 3 | 2022 | 244 | 0.320 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2022 | 2658 | 0.310 |
Why?
|
| Flavoproteins | 4 | 2003 | 24 | 0.300 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2023 | 136 | 0.300 |
Why?
|
| GATA1 Transcription Factor | 7 | 2023 | 20 | 0.290 |
Why?
|
| Down-Regulation | 6 | 2022 | 529 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2019 | 1394 | 0.290 |
Why?
|
| RNA, Messenger | 5 | 2007 | 2063 | 0.290 |
Why?
|
| Transcription Factors | 8 | 2023 | 1717 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-myc | 4 | 2026 | 159 | 0.280 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2021 | 156 | 0.270 |
Why?
|
| Disease Progression | 5 | 2026 | 1609 | 0.260 |
Why?
|
| Membrane Proteins | 5 | 2016 | 1285 | 0.260 |
Why?
|
| WT1 Proteins | 1 | 2007 | 23 | 0.250 |
Why?
|
| CD36 Antigens | 1 | 2006 | 15 | 0.250 |
Why?
|
| Signal Transduction | 9 | 2022 | 3623 | 0.240 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2024 | 461 | 0.240 |
Why?
|
| Translocation, Genetic | 3 | 2016 | 245 | 0.240 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 569 | 0.240 |
Why?
|
| Paresthesia | 1 | 2026 | 24 | 0.240 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2007 | 112 | 0.230 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2026 | 23 | 0.230 |
Why?
|
| Foot | 1 | 2026 | 64 | 0.230 |
Why?
|
| Carcinogenesis | 2 | 2025 | 242 | 0.230 |
Why?
|
| Biomarkers, Tumor | 3 | 2023 | 1764 | 0.220 |
Why?
|
| Erythropoiesis | 2 | 2023 | 53 | 0.210 |
Why?
|
| Male | 29 | 2026 | 47001 | 0.210 |
Why?
|
| B-Lymphocytes | 1 | 2009 | 727 | 0.210 |
Why?
|
| Gene Dosage | 3 | 2018 | 216 | 0.210 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 23 | 0.210 |
Why?
|
| Glutathione Transferase | 3 | 2003 | 116 | 0.210 |
Why?
|
| Lymphoma | 1 | 2026 | 254 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 4 | 2017 | 1416 | 0.210 |
Why?
|
| Myelopoiesis | 2 | 2016 | 12 | 0.200 |
Why?
|
| MDS1 and EVI1 Complex Locus Protein | 2 | 2021 | 7 | 0.200 |
Why?
|
| Chromatin | 3 | 2025 | 454 | 0.200 |
Why?
|
| Chromosomes, Mammalian | 2 | 2021 | 39 | 0.200 |
Why?
|
| Adult | 20 | 2026 | 29458 | 0.200 |
Why?
|
| Cell Proliferation | 9 | 2026 | 1790 | 0.200 |
Why?
|
| Neoplasms | 4 | 2025 | 3340 | 0.200 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 80 | 0.200 |
Why?
|
| Aniline Compounds | 1 | 2023 | 64 | 0.200 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2001 | 144 | 0.190 |
Why?
|
| Middle Aged | 17 | 2026 | 29358 | 0.190 |
Why?
|
| Pyrazines | 1 | 2023 | 98 | 0.190 |
Why?
|
| Isoenzymes | 2 | 2001 | 272 | 0.190 |
Why?
|
| Extracellular Traps | 1 | 2022 | 17 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2014 | 665 | 0.190 |
Why?
|
| Calreticulin | 1 | 2022 | 16 | 0.180 |
Why?
|
| Germ Cells | 1 | 2023 | 137 | 0.180 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2015 | 53 | 0.180 |
Why?
|
| Prognosis | 7 | 2025 | 4112 | 0.180 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.180 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2022 | 46 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2023 | 225 | 0.180 |
Why?
|
| Retroviridae | 1 | 2022 | 74 | 0.180 |
Why?
|
| Female | 26 | 2026 | 51470 | 0.180 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 51 | 0.180 |
Why?
|
| Stem Cells | 2 | 2019 | 396 | 0.180 |
Why?
|
| Thrombopoiesis | 2 | 2023 | 6 | 0.180 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2023 | 285 | 0.180 |
Why?
|
| Biomarkers | 3 | 2022 | 2016 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2014 | 304 | 0.170 |
Why?
|
| Child | 12 | 2018 | 7681 | 0.170 |
Why?
|
| Peroxidase | 1 | 2021 | 54 | 0.170 |
Why?
|
| Heat-Shock Proteins | 4 | 2003 | 178 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 661 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2004 | 582 | 0.170 |
Why?
|
| Platelet Function Tests | 1 | 2020 | 11 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 212 | 0.160 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2021 | 72 | 0.160 |
Why?
|
| Epigenesis, Genetic | 3 | 2021 | 585 | 0.160 |
Why?
|
| Adolescent | 12 | 2025 | 10081 | 0.160 |
Why?
|
| Telomerase | 1 | 2020 | 69 | 0.160 |
Why?
|
| World Health Organization | 2 | 2012 | 125 | 0.160 |
Why?
|
| Aurora Kinase A | 2 | 2019 | 15 | 0.150 |
Why?
|
| Thrombosis | 1 | 2022 | 318 | 0.150 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2020 | 63 | 0.150 |
Why?
|
| Disease-Free Survival | 4 | 2026 | 1193 | 0.150 |
Why?
|
| Gene Expression Profiling | 6 | 2016 | 1565 | 0.150 |
Why?
|
| DNA Repair | 1 | 2021 | 363 | 0.150 |
Why?
|
| Aged | 14 | 2026 | 21704 | 0.150 |
Why?
|
| Cell Lineage | 5 | 2023 | 332 | 0.150 |
Why?
|
| Gene Expression | 5 | 2008 | 1320 | 0.150 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 53 | 0.140 |
Why?
|
| GTPase-Activating Proteins | 1 | 2019 | 71 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 8 | 2021 | 3607 | 0.140 |
Why?
|
| Histiocytosis, Sinus | 1 | 2018 | 17 | 0.140 |
Why?
|
| Cell Nucleus | 3 | 2014 | 615 | 0.140 |
Why?
|
| Macrophages | 4 | 2010 | 643 | 0.140 |
Why?
|
| Genes, abl | 1 | 1998 | 12 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 2019 | 0.130 |
Why?
|
| Influenza, Human | 1 | 2021 | 357 | 0.130 |
Why?
|
| Disease Models, Animal | 7 | 2025 | 2573 | 0.130 |
Why?
|
| Cytogenetic Analysis | 2 | 2021 | 70 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2007 | 1120 | 0.130 |
Why?
|
| Fibrosis | 3 | 2026 | 234 | 0.130 |
Why?
|
| Child, Preschool | 8 | 2017 | 4000 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 639 | 0.130 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 61 | 0.130 |
Why?
|
| Flow Cytometry | 5 | 2016 | 720 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 660 | 0.130 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 2892 | 0.130 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 100 | 0.130 |
Why?
|
| Immunoblotting | 4 | 2013 | 273 | 0.130 |
Why?
|
| Young Adult | 8 | 2025 | 7507 | 0.120 |
Why?
|
| Antibodies, Neoplasm | 2 | 2007 | 87 | 0.120 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2016 | 50 | 0.120 |
Why?
|
| Neoplasm, Residual | 2 | 2022 | 206 | 0.120 |
Why?
|
| Cell Differentiation | 6 | 2015 | 1646 | 0.120 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2007 | 146 | 0.120 |
Why?
|
| Mice, Transgenic | 4 | 2025 | 1605 | 0.120 |
Why?
|
| Chromosome Aberrations | 2 | 2014 | 352 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2016 | 41 | 0.120 |
Why?
|
| Recovery of Function | 1 | 2017 | 371 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 144 | 0.110 |
Why?
|
| Adenoma | 1 | 2017 | 260 | 0.110 |
Why?
|
| Green Fluorescent Proteins | 3 | 2005 | 310 | 0.110 |
Why?
|
| Mice, Knockout | 6 | 2024 | 2206 | 0.110 |
Why?
|
| Granzymes | 1 | 2015 | 96 | 0.110 |
Why?
|
| Pandemics | 1 | 2021 | 913 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2026 | 10953 | 0.110 |
Why?
|
| Cell Line | 4 | 2016 | 2482 | 0.110 |
Why?
|
| Transfection | 6 | 2016 | 883 | 0.110 |
Why?
|
| Chromosomal Instability | 1 | 2014 | 22 | 0.110 |
Why?
|
| Cyclin E | 1 | 2014 | 28 | 0.110 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2014 | 18 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 894 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 291 | 0.100 |
Why?
|
| Genes, myc | 1 | 2014 | 38 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1122 | 0.100 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 4 | 2016 | 20 | 0.100 |
Why?
|
| Mucous Membrane | 1 | 2014 | 82 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 135 | 0.100 |
Why?
|
| Neuroblastoma | 1 | 2017 | 409 | 0.100 |
Why?
|
| Granulocytes | 2 | 2010 | 34 | 0.100 |
Why?
|
| Doxorubicin | 4 | 2007 | 285 | 0.100 |
Why?
|
| Adenosine | 1 | 2016 | 291 | 0.100 |
Why?
|
| Infant | 5 | 2017 | 3329 | 0.100 |
Why?
|
| Stem Cell Factor | 1 | 2013 | 19 | 0.100 |
Why?
|
| Biopsy | 2 | 2014 | 1224 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 297 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 57 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 37 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 188 | 0.100 |
Why?
|
| Stem Cell Niche | 1 | 2013 | 24 | 0.100 |
Why?
|
| Recombination, Genetic | 1 | 2015 | 424 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 505 | 0.090 |
Why?
|
| Vincristine | 3 | 2007 | 102 | 0.090 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 49 | 0.090 |
Why?
|
| Treatment Outcome | 6 | 2024 | 9684 | 0.090 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2010 | 33 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2026 | 7387 | 0.090 |
Why?
|
| Up-Regulation | 2 | 2016 | 743 | 0.090 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 403 | 0.090 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 284 | 0.090 |
Why?
|
| Syndrome | 1 | 2013 | 438 | 0.090 |
Why?
|
| DNA, Complementary | 2 | 2003 | 380 | 0.090 |
Why?
|
| Lymphocytes | 2 | 2008 | 461 | 0.090 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 822 | 0.090 |
Why?
|
| Janus Kinase 2 | 3 | 2019 | 59 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2026 | 3272 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 370 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 889 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 79 | 0.090 |
Why?
|
| India | 4 | 2001 | 148 | 0.090 |
Why?
|
| Hematologic Diseases | 2 | 2012 | 77 | 0.080 |
Why?
|
| Immunotherapy | 1 | 2017 | 821 | 0.080 |
Why?
|
| Apoptosis Inducing Factor | 4 | 2003 | 7 | 0.080 |
Why?
|
| Base Sequence | 4 | 2016 | 2222 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2013 | 388 | 0.080 |
Why?
|
| Phenotype | 3 | 2022 | 2638 | 0.080 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2010 | 13 | 0.080 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 269 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 402 | 0.080 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2009 | 6 | 0.080 |
Why?
|
| Molecular Chaperones | 4 | 2003 | 125 | 0.080 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2010 | 23 | 0.080 |
Why?
|
| Glutathione S-Transferase pi | 2 | 2001 | 18 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2015 | 779 | 0.080 |
Why?
|
| Dexamethasone | 2 | 2022 | 318 | 0.080 |
Why?
|
| Dura Mater | 1 | 2010 | 46 | 0.080 |
Why?
|
| Erythroid-Specific DNA-Binding Factors | 3 | 2003 | 5 | 0.080 |
Why?
|
| T-Lymphocytes | 2 | 2014 | 1331 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 994 | 0.070 |
Why?
|
| Herpesvirus 8, Human | 1 | 2009 | 10 | 0.070 |
Why?
|
| Herpesviridae | 1 | 2009 | 13 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2012 | 324 | 0.070 |
Why?
|
| Autografts | 2 | 2020 | 38 | 0.070 |
Why?
|
| Colony-Forming Units Assay | 2 | 2007 | 39 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2010 | 79 | 0.070 |
Why?
|
| Mitochondria | 2 | 2003 | 647 | 0.070 |
Why?
|
| Cell Survival | 4 | 2016 | 1016 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2015 | 353 | 0.070 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2008 | 73 | 0.070 |
Why?
|
| Mutant Proteins | 2 | 2022 | 98 | 0.070 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 16 | 0.070 |
Why?
|
| Multipotent Stem Cells | 1 | 2008 | 20 | 0.070 |
Why?
|
| Spinal Cord Compression | 1 | 2008 | 50 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 2373 | 0.070 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 48 | 0.070 |
Why?
|
| Proto-Oncogenes | 2 | 2013 | 60 | 0.070 |
Why?
|
| Sacrum | 1 | 2008 | 82 | 0.070 |
Why?
|
| Transcription, Genetic | 4 | 2016 | 1133 | 0.070 |
Why?
|
| Homeostasis | 1 | 2010 | 474 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2026 | 1567 | 0.070 |
Why?
|
| Trisomy | 1 | 2007 | 53 | 0.070 |
Why?
|
| Protein Binding | 2 | 2019 | 1555 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 2555 | 0.060 |
Why?
|
| Spinal Neoplasms | 1 | 2008 | 127 | 0.060 |
Why?
|
| Prednisolone | 1 | 2007 | 37 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 79 | 0.060 |
Why?
|
| Precipitin Tests | 2 | 2003 | 101 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 3 | 2016 | 286 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2015 | 2080 | 0.060 |
Why?
|
| Rare Diseases | 1 | 2007 | 73 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2019 | 1145 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 226 | 0.060 |
Why?
|
| Rituximab | 1 | 2007 | 135 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2009 | 2855 | 0.060 |
Why?
|
| Luminescent Proteins | 2 | 2003 | 142 | 0.060 |
Why?
|
| Spleen | 3 | 2013 | 375 | 0.060 |
Why?
|
| Mutagenesis | 2 | 2003 | 195 | 0.060 |
Why?
|
| Cytosol | 2 | 2003 | 193 | 0.060 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 163 | 0.060 |
Why?
|
| Genomics | 2 | 2022 | 898 | 0.060 |
Why?
|
| Wnt1 Protein | 1 | 2025 | 27 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2003 | 731 | 0.050 |
Why?
|
| Lung | 2 | 2022 | 1406 | 0.050 |
Why?
|
| Age Factors | 2 | 2001 | 1960 | 0.050 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 1998 | 262 | 0.050 |
Why?
|
| Germ-Free Life | 1 | 2025 | 88 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 376 | 0.050 |
Why?
|
| Remission Induction | 2 | 2012 | 754 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2005 | 582 | 0.050 |
Why?
|
| Preleukemia | 1 | 2024 | 10 | 0.050 |
Why?
|
| Cytochrome c Group | 2 | 2003 | 82 | 0.050 |
Why?
|
| Mixed Function Oxygenases | 2 | 2016 | 68 | 0.050 |
Why?
|
| Cytochromes c | 1 | 2004 | 28 | 0.050 |
Why?
|
| Acute Disease | 3 | 2016 | 857 | 0.050 |
Why?
|
| Cell Movement | 2 | 2019 | 815 | 0.050 |
Why?
|
| Rats | 4 | 2004 | 4070 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 2 | 2001 | 20 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2003 | 84 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 1028 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 47 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 54 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2022 | 1098 | 0.050 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 99 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2003 | 107 | 0.050 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 663 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 89 | 0.050 |
Why?
|
| In Situ Hybridization | 2 | 2021 | 306 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2012 | 1005 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2003 | 276 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2022 | 42 | 0.050 |
Why?
|
| Imides | 1 | 2022 | 27 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2024 | 218 | 0.050 |
Why?
|
| X-Box Binding Protein 1 | 1 | 2022 | 21 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 106 | 0.050 |
Why?
|
| Philadelphia Chromosome | 1 | 2022 | 48 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 52 | 0.050 |
Why?
|
| Interleukin-4 | 1 | 2022 | 136 | 0.050 |
Why?
|
| Abnormal Karyotype | 1 | 2022 | 8 | 0.050 |
Why?
|
| Protein Isoforms | 1 | 2023 | 303 | 0.050 |
Why?
|
| Curriculum | 1 | 2007 | 633 | 0.050 |
Why?
|
| Time Factors | 3 | 2016 | 5557 | 0.040 |
Why?
|
| Karyotype | 1 | 2022 | 34 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2002 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2003 | 435 | 0.040 |
Why?
|
| DNA Mutational Analysis | 3 | 2014 | 548 | 0.040 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 132 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1536 | 0.040 |
Why?
|
| Protein Transport | 1 | 2003 | 447 | 0.040 |
Why?
|
| Cell-Free System | 1 | 2001 | 45 | 0.040 |
Why?
|
| Models, Biological | 4 | 2019 | 1805 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2022 | 93 | 0.040 |
Why?
|
| Symbiosis | 1 | 2022 | 130 | 0.040 |
Why?
|
| Plasmids | 1 | 2001 | 275 | 0.040 |
Why?
|
| Autopsy | 1 | 2021 | 131 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 642 | 0.040 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 15 | 0.040 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2000 | 18 | 0.040 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2000 | 29 | 0.040 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 1061 | 0.040 |
Why?
|
| Risk | 2 | 2012 | 660 | 0.040 |
Why?
|
| Biology | 1 | 2020 | 53 | 0.040 |
Why?
|
| Cell Division | 1 | 2001 | 689 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 1027 | 0.040 |
Why?
|
| Transcriptome | 2 | 2016 | 820 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2001 | 263 | 0.040 |
Why?
|
| Peptides | 1 | 2003 | 670 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2013 | 4799 | 0.040 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2019 | 4 | 0.040 |
Why?
|
| Seasons | 1 | 2021 | 252 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2019 | 16 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 369 | 0.040 |
Why?
|
| Telomere | 1 | 2020 | 130 | 0.040 |
Why?
|
| Oligopeptides | 1 | 2020 | 205 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2007 | 2581 | 0.040 |
Why?
|
| Genes, MDR | 1 | 1998 | 7 | 0.030 |
Why?
|
| Myeloid Progenitor Cells | 2 | 2008 | 16 | 0.030 |
Why?
|
| Fibroblasts | 1 | 2001 | 766 | 0.030 |
Why?
|
| Caspases | 3 | 2003 | 151 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2001 | 332 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1998 | 214 | 0.030 |
Why?
|
| Bacteria | 1 | 2022 | 545 | 0.030 |
Why?
|
| Calcium | 1 | 2022 | 1196 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 256 | 0.030 |
Why?
|
| Hepatitis B | 1 | 1998 | 78 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2018 | 110 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2017 | 89 | 0.030 |
Why?
|
| Retinoic Acid Receptor alpha | 1 | 2016 | 18 | 0.030 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 20 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1274 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 2017 | 47 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2012 | 730 | 0.030 |
Why?
|
| Anemia | 1 | 2018 | 135 | 0.030 |
Why?
|
| Alemtuzumab | 2 | 2007 | 90 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2017 | 113 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 2017 | 214 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1384 | 0.030 |
Why?
|
| Prednisone | 2 | 2007 | 251 | 0.030 |
Why?
|
| Tretinoin | 1 | 2016 | 130 | 0.030 |
Why?
|
| Fatal Outcome | 2 | 2007 | 295 | 0.030 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2015 | 4 | 0.030 |
Why?
|
| Polyploidy | 1 | 2015 | 15 | 0.030 |
Why?
|
| Proteins | 1 | 2001 | 803 | 0.030 |
Why?
|
| Azepines | 1 | 2015 | 29 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2015 | 61 | 0.030 |
Why?
|
| Methylation | 1 | 2016 | 294 | 0.030 |
Why?
|
| Hepatitis C | 1 | 1998 | 186 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 102 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2015 | 83 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2015 | 162 | 0.030 |
Why?
|
| I-kappa B Kinase | 1 | 2015 | 42 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2016 | 420 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 317 | 0.030 |
Why?
|
| Nitriles | 1 | 2015 | 171 | 0.030 |
Why?
|
| Integrases | 1 | 2015 | 68 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 271 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 173 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 164 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 215 | 0.030 |
Why?
|
| Positron-Emission Tomography | 2 | 2007 | 354 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2015 | 160 | 0.030 |
Why?
|
| Sex Factors | 1 | 1998 | 1137 | 0.030 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Heterozygote | 1 | 2015 | 390 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 1946 | 0.030 |
Why?
|
| Protein Stability | 1 | 2014 | 105 | 0.030 |
Why?
|
| Genes, p53 | 1 | 2014 | 108 | 0.030 |
Why?
|
| Nanoparticles | 1 | 2016 | 218 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2016 | 718 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 129 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 334 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2013 | 96 | 0.020 |
Why?
|
| Etoposide | 2 | 2004 | 207 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 196 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 102 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 139 | 0.020 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2013 | 68 | 0.020 |
Why?
|
| Binding Sites | 1 | 2016 | 1158 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2015 | 411 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 107 | 0.020 |
Why?
|
| Genes, Neoplasm | 1 | 2012 | 39 | 0.020 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 55 | 0.020 |
Why?
|
| Cytosine | 1 | 2013 | 124 | 0.020 |
Why?
|
| U937 Cells | 2 | 2003 | 32 | 0.020 |
Why?
|
| Thrombocytosis | 1 | 2012 | 9 | 0.020 |
Why?
|
| Calcineurin | 1 | 2012 | 20 | 0.020 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2003 | 32 | 0.020 |
Why?
|
| Pedigree | 1 | 2014 | 980 | 0.020 |
Why?
|
| 5-Methylcytosine | 1 | 2013 | 134 | 0.020 |
Why?
|
| Mitoxantrone | 1 | 2012 | 65 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 246 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 218 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 700 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 180 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 310 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 194 | 0.020 |
Why?
|
| United States | 1 | 2024 | 8184 | 0.020 |
Why?
|
| GATA2 Transcription Factor | 1 | 2009 | 16 | 0.020 |
Why?
|
| Erythroid Cells | 1 | 2009 | 17 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 902 | 0.020 |
Why?
|
| Genotype | 2 | 2007 | 1888 | 0.020 |
Why?
|
| Recurrence | 1 | 2012 | 1254 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 2893 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1229 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1750 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 1110 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1995 | 0.020 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2007 | 62 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 217 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 975 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 66 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 762 | 0.020 |
Why?
|
| Exons | 1 | 2007 | 451 | 0.010 |
Why?
|
| Incidence | 2 | 2001 | 1777 | 0.010 |
Why?
|
| DNA, Antisense | 1 | 2004 | 15 | 0.010 |
Why?
|
| HT29 Cells | 1 | 2004 | 50 | 0.010 |
Why?
|
| Staurosporine | 1 | 2004 | 34 | 0.010 |
Why?
|
| Peptide Mapping | 1 | 2003 | 24 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2003 | 47 | 0.010 |
Why?
|
| HCT116 Cells | 1 | 2004 | 163 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 38 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 2003 | 96 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2003 | 161 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2003 | 72 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 112 | 0.010 |
Why?
|
| Ubiquitin | 1 | 2003 | 95 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1850 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2003 | 276 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 2558 | 0.010 |
Why?
|
| Cell Death | 1 | 2003 | 257 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 426 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 578 | 0.010 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2001 | 8 | 0.010 |
Why?
|
| Chaperonin 60 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 20 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 2001 | 82 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 2001 | 81 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2001 | 53 | 0.010 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2001 | 45 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2003 | 925 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 423 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2001 | 168 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 313 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 707 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2000 | 124 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2001 | 479 | 0.010 |
Why?
|
| Stress, Physiological | 1 | 2001 | 255 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2003 | 1391 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2003 | 1145 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 679 | 0.010 |
Why?
|
| Research | 1 | 2000 | 256 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 2529 | 0.010 |
Why?
|